Arcus Biosciences (RCUS) Competitors $16.47 +0.74 (+4.70%) (As of 11/7/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends RCUS vs. KRYS, OGN, BHVN, BBIO, RARE, ACLX, RNA, CRNX, ADMA, and IMVTShould you be buying Arcus Biosciences stock or one of its competitors? The main competitors of Arcus Biosciences include Krystal Biotech (KRYS), Organon & Co. (OGN), Biohaven (BHVN), BridgeBio Pharma (BBIO), Ultragenyx Pharmaceutical (RARE), Arcellx (ACLX), Avidity Biosciences (RNA), Crinetics Pharmaceuticals (CRNX), ADMA Biologics (ADMA), and Immunovant (IMVT). These companies are all part of the "pharmaceutical products" industry. Arcus Biosciences vs. Krystal Biotech Organon & Co. Biohaven BridgeBio Pharma Ultragenyx Pharmaceutical Arcellx Avidity Biosciences Crinetics Pharmaceuticals ADMA Biologics Immunovant Arcus Biosciences (NYSE:RCUS) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk, institutional ownership and community ranking. Does the media prefer RCUS or KRYS? In the previous week, Krystal Biotech had 17 more articles in the media than Arcus Biosciences. MarketBeat recorded 33 mentions for Krystal Biotech and 16 mentions for Arcus Biosciences. Krystal Biotech's average media sentiment score of 0.68 beat Arcus Biosciences' score of 0.23 indicating that Krystal Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcus Biosciences 2 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Krystal Biotech 8 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in RCUS or KRYS? 92.9% of Arcus Biosciences shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 12.3% of Arcus Biosciences shares are owned by company insiders. Comparatively, 14.1% of Krystal Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more volatility and risk, RCUS or KRYS? Arcus Biosciences has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500. Is RCUS or KRYS more profitable? Krystal Biotech has a net margin of 21.68% compared to Arcus Biosciences' net margin of -100.81%. Krystal Biotech's return on equity of 7.54% beat Arcus Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Arcus Biosciences-100.81% -42.86% -20.90% Krystal Biotech 21.68%7.54%6.97% Which has stronger valuation & earnings, RCUS or KRYS? Krystal Biotech has lower revenue, but higher earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcus Biosciences$117M12.87-$307M-$3.09-5.33Krystal Biotech$50.70M105.09$10.93M$1.77104.77 Do analysts recommend RCUS or KRYS? Arcus Biosciences currently has a consensus price target of $34.13, suggesting a potential upside of 107.19%. Krystal Biotech has a consensus price target of $197.00, suggesting a potential upside of 6.23%. Given Arcus Biosciences' higher possible upside, research analysts plainly believe Arcus Biosciences is more favorable than Krystal Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcus Biosciences 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00Krystal Biotech 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor RCUS or KRYS? Krystal Biotech received 92 more outperform votes than Arcus Biosciences when rated by MarketBeat users. Likewise, 67.14% of users gave Krystal Biotech an outperform vote while only 65.54% of users gave Arcus Biosciences an outperform vote. CompanyUnderperformOutperformArcus BiosciencesOutperform Votes19465.54% Underperform Votes10234.46% Krystal BiotechOutperform Votes28667.14% Underperform Votes14032.86% SummaryKrystal Biotech beats Arcus Biosciences on 12 of the 17 factors compared between the two stocks. Ad Porter & CompanyWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. Get Arcus Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RCUS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RCUS vs. The Competition Export to ExcelMetricArcus BiosciencesPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$1.51B$6.88B$5.27B$20.00BDividend YieldN/A7.97%4.65%3.55%P/E Ratio-5.338.20119.4341.74Price / Sales12.87422.031,326.2117.59Price / CashN/A46.2438.8920.67Price / Book2.677.655.705.24Net Income-$307M$154.37M$118.38M$988.95M7 Day Performance6.26%2.27%4.11%4.38%1 Month Performance-5.67%18.79%11.10%3.89%1 Year Performance2.87%42.88%39.04%30.13% Arcus Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RCUSArcus Biosciences3.0508 of 5 stars$16.47+4.7%$34.13+107.2%-0.2%$1.51B$117M-5.33500Earnings ReportAnalyst ForecastGap UpHigh Trading VolumeKRYSKrystal Biotech4.5498 of 5 stars$176.39+2.2%N/A+70.1%$4.96B$50.70M48.33229Earnings ReportAnalyst ForecastAnalyst RevisionHigh Trading VolumeOGNOrganon & Co.4.8867 of 5 stars$18.07-3.8%N/A+29.9%$4.84B$6.26B3.5910,000BHVNBiohaven3.052 of 5 stars$50.88+2.3%N/A+75.4%$4.81B$462.51M-5.56239Upcoming EarningsPositive NewsBBIOBridgeBio Pharma4.6041 of 5 stars$25.48+8.8%N/A-11.9%$4.79B$219.12M-9.69400RAREUltragenyx Pharmaceutical4.6902 of 5 stars$50.99flatN/A+32.4%$4.70B$434.25M-6.981,276Earnings ReportAnalyst ForecastAnalyst RevisionACLXArcellx1.358 of 5 stars$86.17+2.3%N/A+107.7%$4.63B$110.32M-82.86130Upcoming EarningsAnalyst ForecastNews CoverageRNAAvidity Biosciences2.0046 of 5 stars$41.87-0.9%N/A+714.9%$4.60B$9.56M-14.24190Upcoming EarningsCRNXCrinetics Pharmaceuticals3.6098 of 5 stars$56.69+1.3%N/A+102.6%$4.54B$1.39M-15.00210Upcoming EarningsADMAADMA Biologics2.6479 of 5 stars$19.37+18.8%N/A+434.4%$4.51B$258.21M138.36530Gap UpHigh Trading VolumeIMVTImmunovant2.7253 of 5 stars$29.39+0.4%N/A-13.5%$4.28BN/A-15.23120Upcoming Earnings Related Companies and Tools Related Companies Krystal Biotech Competitors Organon & Co. Competitors Biohaven Competitors BridgeBio Pharma Competitors Ultragenyx Pharmaceutical Competitors Arcellx Competitors Avidity Biosciences Competitors Crinetics Pharmaceuticals Competitors ADMA Biologics Competitors Immunovant Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:RCUS) was last updated on 11/8/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredThe secret supplier behind NVIDIA, Tesla and MicrosoftThe Biggest AI firms in the world...Tesla... Microsoft... NVIDIA... Are all relying on a little-known suppl...Behind the Markets | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredTrump’s Victory Just Kicked the Door Open to a…This story is about a division that has been splitting America apart at the seams for the past three and a hal...Banyan Hill Publishing | SponsoredUrgent: This election is riggedI’d like to share with you my #1 high-conviction stock to buy before Inauguration Day… and details on the asse...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcus Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
